6/29/23, 1:37 AM PEXIVAS (plasmapheresis) Pathway Feedback Search Clinical Topics Home Studies PEXIVAS (plasmapheresis) PEXIVAS (plasmapheresis) DiseaseEosinophilic granulomatosis wit DiseaseGranulomatosis with polyangiitis DiseaseMicroscop Trial question What is the role of plasma exchange in patients with severe ANCA-associated vasculitis? Study design Multi-center Open label RCT Population Characteristics of study participants 44.0% female 56.0% male 704 patients (307 female, 397 male) Inclusion criteria: patients with severe ANCA-associated vasculitis Key exclusion criteria: age < 15 years; plasma exchange within 3 months' diagnosis of vasculitis; pregnancy Interventions N=352 plasma exchange (seven plasma exchanges within 14 days after randomization) N=352 no plasma exchange (no exchange of plasma) Primary outcome Composite outcome of death from any cause or end-stage kidney disease 31 https://web.pathway.md/studies/recImZqBZg1Kb2Iw4 1/2 6/29/23, 1:37 AM PEXIVAS (plasmapheresis) Pathway 3 31.0 % 28.4 23.3 % 15.5 % 7.8 % 0.0 % Plasma exchange No plasma exchange No significant difference in composite outcome of death from any cause or end-stage kidney disease (28.4% vs. 31%; HR 0.86, 95% CI 0.65 to 1.13) Safety outcomes No significant differences in serious adverse events, serious infections at 1 year. Conclusion In patients with severe ANCA-associated vasculitis, plasma exchange was not superior to no plasma exchange with respect to the composite outcome of death from any cause or end-stage kidney disease. Reference Michael Walsh, Peter A Merkel, Chen-Au Peh et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631. Open reference URL https://web.pathway.md/studies/recImZqBZg1Kb2Iw4 2/2